Vor Bio appoints Qing Zuraw as chief development officer

CAMBRIDGE, Mass. - Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company focused on autoimmune diseases with a market capitalization of $265 million and impressive 91% year-to-date stock performance, announced Thursday the appointment of Qing Zuraw, M.D., M.P.H., M.B.A., as Chief Development Officer, effective immediately. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 3.88, though it faces significant operational challenges with negative EBITDA of $119 million.

Dr. Zuraw brings over 25 years of experience in clinical development across autoimmune, inflammatory, and immunologic diseases. She previously served as Chief Development Officer and Head of Global Clinical Development for Autoimmune Diseases at RemeGen Co., Ltd., where she led development programs for telitacicept across multiple indications.

At RemeGen, Dr. Zuraw oversaw successful clinical trials for telitacicept in systemic lupus erythematosus, Sjögren’s syndrome, myasthenia gravis, and rheumatoid arthritis, which resulted in regulatory approvals in China for three of these conditions.

Prior to RemeGen, Dr. Zuraw held senior leadership positions at Janssen Research & Development, Teva Pharmaceutical Industries, Akebia Therapeutics, Biogen, and Covance. Her experience includes contributing to the FDA approval of Guselkumab for psoriatic arthritis and multiple NDA and BLA submissions.

"We are delighted to welcome Qing to Vor Bio at a critical time for the company," said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board, according to the company’s press release. InvestingPro analysis reveals several key insights about Vor Bio’s current position, with 13 additional ProTips available to subscribers. The company’s next earnings report is scheduled for August 7, which could provide crucial updates on its development programs.

Vor Bio is currently advancing telitacicept, a dual-target fusion protein, through Phase 3 clinical development for autoantibody-driven conditions. For detailed analysis of Vor Bio’s financial health, development pipeline, and growth prospects, access the comprehensive Pro Research Report, available exclusively on InvestingPro, along with in-depth reports on 1,400+ other US stocks.

In other recent news, Vor Bio has made significant strides with several key developments. The company announced a private placement agreement expected to generate approximately $175 million in gross proceeds, which will be used to advance its clinical pipeline, notably telitacicept, a dual-target fusion protein in Phase 3 development for autoimmune diseases. Vor Bio also entered into an exclusive licensing agreement with RemeGen Co., Ltd., granting it global rights to develop and commercialize telitacicept outside of China. This deal includes an upfront payment of $125 million and potential milestone payments exceeding $4 billion. Following this, H.C. Wainwright upgraded Vor Biopharma from Neutral to Buy, citing the acquisition of a "de-risked asset" as a key factor. In leadership changes, Sandy Mahatme was appointed as Chief Financial Officer and Chief Business Officer, bringing extensive experience from previous roles at National Resilience, Inc. and Sarepta Therapeutics. Additionally, Jean-Paul Kress was named Chief Executive Officer and Chairman of the Board, replacing Robert Ang. Meanwhile, Stifel maintained its Hold rating on Vor Biopharma, acknowledging the company’s strategic shift from oncology to autoimmune diseases. These developments mark a period of transformation and repositioning for Vor Bio.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.